Supernus Pharmaceuticals (SUPN) Earnings Date, Estimates & Call Transcripts

Supernus Pharmaceuticals logo
$28.83 -0.89 (-2.99%)
As of 04:00 PM Eastern

Supernus Pharmaceuticals Earnings Summary

Supernus Pharmaceuticals issued Q3 2026 earnings on October 29, 2026, reporting an EPS of $0.35, which missed the consensus estimate of $0.49 by $0.14. Quarterly revenue rose 18.0% year-over-year to $208.60 million, below analyst estimates of $217.56 million. With a trailing EPS of $3.58 and a P/E Ratio of 8.05, Supernus Pharmaceuticals' earnings are expected to decrease -0.53% next year, from $3.80 to $3.78 per share.

Latest Q3
Earnings Date
Oct. 29Estimated
Consensus EPS
(Oct. 29)
$0.49
Actual EPS
(Oct. 29)
$0.35 Missed By -$0.14
Actual Revenue
(Oct. 29)
$208.60M

Q3 2026 Earnings Resources

Get Supernus Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Supernus Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

SUPN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SUPN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Supernus Pharmaceuticals Analyst EPS Estimates

Current Year EPS Consensus Estimate
$3.80 EPS
Next Year EPS Consensus Estimate
$3.78 EPS

Supernus Pharmaceuticals Earnings History by Quarter

Report Date
0 Results
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026$0.49$0.35 -$0.14$0.35$217.56M$208.60M
8/3/2026Q2 2026 & Merger$0.4225-$1.01 -$1.4325-$1.01$205.31M$219.06M
11/4/2025Q3 2025$0.82$0.46 -$0.36-$0.80$175.82M$170.00M
5/6/2025Q1 2025$0.26$0.28+$0.02-$0.21$145.59M$149.82M

Supernus Pharmaceuticals Earnings - Frequently Asked Questions

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earning data on Thursday, October 29, 2026. Learn more on SUPN's earnings history.

In the previous quarter, Supernus Pharmaceuticals (NASDAQ:SUPN) missed the analysts' consensus estimate of $0.49 by $0.14 with a reported earnings per share (EPS) of $0.35. Learn more on analysts' earnings estimate vs. SUPN's actual earnings.

The conference call for Supernus Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Supernus Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Supernus Pharmaceuticals' earnings report can be found in their filing with the SEC.
View SEC filing

Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded annual revenue of $1.24 billion.

Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded net income of $210 million. SUPN has generated $3.58 earnings per share over the last four quarters.

Supernus Pharmaceuticals (NASDAQ:SUPN) has a trailing price-to-earnings ratio of 8.05 and a forward price-to-earnings ratio of 7.63. The price/earnings-to-growth ratio is 0.59.

Supernus Pharmaceuticals' earnings are expected to decrease from $3.80 per share to $3.78 per share in the next year, which is a -0.53% change.


Earnings data for NASDAQ:SUPN is sourced from Fiscal.ai, with the most recent quarter reported on 10/29/2026. New results are added as companies report their earnings.
From Our Partners